Statistics from Altmetric.com
We thank Plüß et al for their interest in our study reporting on the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) in a case series of patients with systemic lupus erythematosus (SLE) under long-term treatment with hydroxychloroquine (HCQ).1 2 Plüß et al highlight a major point with respect to the consequences of the SARS-CoV2 outbreak on patients with SLE, in particular the difficulties that the latter have experienced in securing HCQ supplies for a licensed indication as a consequence of the off-label use of this drug to treat COVID-19 in the general population.
Plüß et al report that 70% of patients with SLE in Germany expressed concerns regarding the inability to receive their prescriptions for HCQ which was furthermore underscored by the observation that 46% also reported HCQ …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.